2023 Cancer Care Report, Marie Yeager Cancer Center - Southwest Michigan

2023

Cancer Care Report

Data collected in 2022 and reported in 2023

Each year we look at cancer cases locally and nationally in order to understand trends, support cancer research, measure progress in prevention efforts, and to improve cancer outcomes.

As an accredited organization we have proven ourselves through legitimate third parties that we meet or exceed strict quality standards.

•

Accredited with commendation by the Commission on Cancer (CoC) of the American College of Surgeons (ACoS) as a Community Hospital Comprehensive Cancer Program.

•

The Radiation Oncology Department is accredited by the American College of Radiology (ACR).

•

Fully accredited by the National Accreditation Program for Breast Centers (NAPBC), a program administered by the American College of Surgeons.

•

Member of the American Society of Clinical Oncology (ASCO).

•

Member of the American Society for Radiation Oncology (ASTRO).

•

Gold seal of approval from The Joint Commission.

•

Participates in the Michigan Radiation Oncology Quality Consortium and the Cancer Research Consortium of West Michigan.

Read on to learn more about cancer cases from 2022 in Michigan, the United States, and at Corewell Health Lakeland Hospitals specifically.

spectrumhealthlakeland.org/cancer-care

2023 Cancer Care Report

Statistical summary and review of registry data 2022

Non-analytic cases are those that were diagnosed and received all first course treatment elsewhere, and came to Corewell Health for subsequent treatment for either recurrence or persistence of their disease.

In 2022, 1,339 cases were added to the Corewell Health in Southwest Michigan Cancer Registry. Of these cases, 1,206 cases were considered analytic, which means that they received all or part of their first course treatment locally, or were diagnosed by Corewell Health in Southwest Michigan and received all first course treatment elsewhere. The number of cisgender males were 601 (44.89%), cisgender female were 736 (54.97%), transgender female was one (0.7%), and transgender male was one (0.7%).

Patients diagnosed at age 60 years or older accounted for 72.97% of cases.

Patients 30 through 59 years of age accounted for 25.16%, while 1.87% of cases were 29 years old or younger. The mean age of cancer patients in 2022 was 65.

Figure 1a 2022 ratio of female to male patients

.07%

Transgender male at birth

54.97% 44.89% 736 Females

601 Males

Figure 1b 2022 age distribution

.07%

72.97% 25.16%

Transgender female at birth

60 Years and older

Ages 30-59

1.87%

Age 29 and younger

Figure 2 Percent distribution of Corewell Health Lakeland Hospitals’ 2022 cancer cases by age decade

Percent distribution

35% 27.86% 28.98%

30% 25% 20%

15.39%

15% 10% 5% 0%

1.87% 0-29

4.70%

5.07%

30-39

40-49

13.52%

2.61% 50-59

60-69

Age decade

70-79

Page 1

80-89

90+

Page 2

2023 Cancer Care Report

Table 1 Site distribution by stage for the four most common cancer sites at Corewell Health Lakeland Hospitals* Cases

Stage 0

Stage I

Stage II

Stage III

Stage IV

UNK Staged

Breast

185

29

108

27

12

7

2

Lung

181

0

52

13

29

85

2

Prostate

134

0

31

45

26

20

12

Colorectal

109

8

20

19

29

29

4

Table 2 Comparison of four most common cancer sites, Corewell Health Lakeland Hospitals, state of Michigan, and United States

Corewell Health Lakeland Hospitals

Michigan

United States

Rank

Cases

% of Total

Rank

% of Total

Rank

% of Total

Breast

1

185

13.81%

2

14.28%

1

15.00%

Lung

2

181

13.51%

3

13.95%

3

12.34%

Prostate

3

134

10.00%

1

14.78%

2

13.99%

Colon/rectum

4

109

8.14%

4

7.48%

4

7.87%

Site

*American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022, pg 4-5.

Table 3 Comparison of percent distribution of Corewell Health Lakeland Hospitals 2022 cancer cases and United States data by gender and four most common cancer sites

Male Cancer Cases Site

Female Cancer Cases

United States*

Lakeland

United States*

Lakeland

Breast

0.27%

0.33%

30.79%

24.86%

Prostate

27.30%

22.29%

NA

NA

Lung

11.99%

14.47%

12.71%

12.77%

Colorectal

8.20%

8.48%

7.52%

7.88%

*American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022 pg 4.

2023 Cancer Care Report

Page 3

Figure 3 Comparison of percent distributions of Corewell Health Lakeland Hospitals three most common female and male cancer sites for 2022 and United States data*

Female

35% 30.79%

30% 25%

30% 24.90%

25%

20%

27.30% 22.30%

20%

15%

12.80%

14.50%

15%

12.71%

10%

7.90%

7.52%

5% 0%

Male

35%

11.99%

10%

8.50%

8.20%

5%

Breast

Lung

Corewell Health Lakeland Hospitals

Colorectal

0%

United States*

Prostate

Lung

Colorectal

*American Cancer Society. Cancer Facts & Figures 2022.

Atlanta: American Cancer Society; 2022, pg 4.

Figure 4 Comparison of percent distribution of Corewell Health Lakeland Hospitals’ 2022 cancer cases by gender Breast - 183 (25%)

Prostate - 134 (22%)

Lung & Bronchus - 94 (13%)

Lung & Bronchus - 87 (15%)

Uterine Corpus - 48 (6%)

Colon & Rectum - 51 (9%)

Colon & Rectum - 58 (8%)

Non-Hodgkin Lymphoma - 16 (3%)

Kidney & Renal Pelvis - 15 (2%)

Urinary Bladder - 38 (6%)

Melanoma of the Skin - 20 (3%)

Kidney & Renal Pelvis - 29 (5%)

Leukemia - 17 (2%)

Leukemia - 18 (3%)

Non-Hodgkin Lymphoma - 12 (2%)

Melanoma of the Skin - 22 (4%)

Thyroid - 8 (1%)

Oral Cavity & Pharynx - 20 (3%)

Ovary - 8 (1%)

Pancreas - 21 (3%)

All Other Sites - 273 (37%)

All Other Sites - 165 (27%)

Female

Male

Page 4

2023 Cancer Care Report

Figure 5a Distribution of Corewell Health Lakeland Hospitals cancer cases by county

All other Michigan Counties

.67%

Lake Michigan

Van Buren County

5.75% Berrien County

83.20%

Cass County

9.04%

Out of State 1.34%

Figure 5b Distribution of Corewell Health Lakeland Hospitals cancer cases by city (Berrien, Cass, Van Buren counties) 20%

19.19%

16% 13.20% 12.99%

14% 12% 10% 8%

6.79%

6%

5.89%

5.30% 5.00%

257

178

174

91

79

71

67

52

48

32

30

27

23

20

18

Stevensville

Dowagiac

Berrien Springs

Coloma

Buchanan

Watervliet

Hartford

Bridgman

Cassopolis

Eau Claire

Baroda

Three Oaks

0%

2.38% 2.24% 2.00% 1.71% 1.49% 1.34%

Niles

2%

3.88% 3.58%

St. Joseph

4%

Benton Harbor

Percent distribution

18%

City

2023 Cancer Care Report

Figure 6 Distribution of total cancer cases by primary site Breast

185

Lung and Bronchus Lung and Bronchus

181

Breast Prostate

Prostate

134

BenignBrain/Cranial Brain/Cranial Nerves Benign Nerves

106

Colon

76

Female Female GenitalGenital System System

74

Colon

*CIN III Non-Hodgkins Lymphoma

68

Bladder

46

& R enal Pelvis Kidney &Kidney Renal Pelvis

44

Bladder

Melanoma

42

*CIN III

Leukemia

36

Melanoma

Pancreas

34

Rectum and rectosigmoid Benign Endocrine

33

Miscellaneous

31

Oral Cavity &Benign PharynxEndocrine

30

Pancreas Non-Hodgkins Lymphoma

28

Rectum Oral Cavity & Pharynx

26

Myeloma

24

Esophagus

21

Malignant Thyroid/Endocrine Liver & Intrahepatic Bile Duct

17

Esophagus

Larynx

16

Liver & Intrahepatic Bile Duct Malignant Thyroid/Endocrine

14

Larynx Brain/Cranial Nerves Malignant

12

Malignant Brain/Cranial Nerves Stomach

12

Anus, Anal Canal & Anorectum Small Intestine

10

Soft Tissue Anus, Anal Canal & Anorectum

8

Leukemia

Myeloma

Stomach Miscellaneous

Gallbladder

Testis

7

Small Intestine Hodgkin Lymphoma

3

Testis

Gallbladder

3

Mesothelioma Mesothelioma Hodgkin LymphomaBone/Joint

2

Bone/Joint

Soft Tissue

1 1

0 is accessioned by agreement, 50 but for 2022 the collection 100 of this data was mandated 150by the State of Michigan200 *CIN III (non-invasive cervical severe dysplasia)

Page 5

Page 6

2023 Cancer Care Report

Table 4 Summary: By body, system, and gender Primary Site

Total

Percent

Male

Percent

Female

Percent

BRAIN & OTHER NERVOUS SYSTEM

118

8.8%

42

6.8%

76

10.3%

Brain

19

1.4%

12

2.0%

7

0.9%

Cranial Nerves other Nervous System

99

7.4%

30

4.8%

69

9.4%

BONES & JOINTS

1

0.1%

0

0.0%

1

0.1%

BREAST

185

13.8%

2

0.3%

183

24.8%

DIGESTIVE SYSTEM

218

16.3%

121

20.1%

97

13.2%

Anus, Anal Canal & Anorectum

8

0.6%

3

0.5%

5

0.7%

Colon Excluding Rectum

76

5.7%

31

5.2%

45

6.1%

Esophagus

21

1.6%

20

3.3%

1

0.1%

Gallbladder

3

0.2%

0

0.0%

3

0.4%

Liver & Intrahepeatic Bile Duct

17

1.3%

9

1.5%

8

1.1%

Rectum & Rectosigmoid

33

2.5%

20

3.3%

13

1.8%

Small Intestine

10

0.7%

5

0.8%

5

0.7%

Stomach

12

0.9%

11

1.8%

1

0.1%

Other Biliary

3

0.2%

1

0.2%

2

0.3%

Pancreas

34

2.5%

21

3.5%

13

1.8%

Peritoneum, Omentum & Mecenter

1

0.1%

0

0.0%

1

0.1%

ENDOCRINE SYSTEM

44

3.3%

14

2.3%

30

4.1%

Thyroid

12

0.9%

4

0.7%

8

1.1%

Other Endocrine including Thymus

32

2.4%

10

1.7%

22

3.0%

EYE & ORBIT

1

0.1%

0

0.0%

1

0.1%

FEMALE GENITAL SYSTEM

142

10.6%

0

0.0%

142

19.1%

Cervix Uteri

78

5.8%

0

0.0%

78

10.4%

Corpus & Uterus, NOS

48

3.6%

0

0.0%

48

6.6%

Ovary

8

0.6%

0

0.0%

8

1.1%

Vagina

1

0.1%

0

0.0%

1

0.1%

Vulva

6

0.4%

0

0.0%

6

0.8%

Other Female Genital Organs

1

0.1%

0

0.0%

1

0.1%

LEUKEMIA

35

2.7%

18

3.0%

17

2.4%

Lymphocytic Leukemia

19

1.5%

9

1.5%

10

1.5%

Myeloid & Monocytic Leukemia

15

1.1%

8

1.3%

7

0.9%

Other Leukemia

1

0.1%

1

0.2%

0

0.0%

2023 Cancer Care Report

Page 7

Table 4 (continued) Summary: By body, system, and gender Primary Site

Total

Percent

Male

Percent

Female

Percent

LYMPHOMA

31

2.3%

18

3.0%

13

1.8%

Hodgkins Lymphoma

3

0.2%

2

0.3%

1

0.1%

Non-Hodgkin Lymphoma

28

2.1%

16

2.7%

12

1.6%

MALE GENITAL SYSTEM

141

10.5%

141

23.5%

0

0.0%

Prostate

134

10.0%

134

22.3%

0

0.0%

Testis

7

0.5%

7

1.2%

0

0.0%

MESOTHELIOMA

2

0.1%

2

0.3%

0

0.0%

MYELOMA

24

1.8%

15

2.5%

9

1.2%

ORAL CAVITY & PHARYNX

26

1.9%

20

3.3%

6

0.8%

Tongue

13

1.0%

12

2.0%

1

0.1%

Salivary Glands

2

0.1%

1

0.2%

1

0.1%

Floor of Mouth

1

0.1%

1

0.2%

0

0.0%

Gum & Other Mouth

2

0.1%

1

0.2%

1

0.1%

Nasopharynx

1

0.1%

1

0.2%

0

0.0%

Tonsil

7

0.5%

4

0.7%

3

0.4%

RESPIRATORY SYSTEM

198

14.8%

100

16.6%

98

13.3%

Larynx

16

1.2%

13

2.2%

3

0.4%

Lung & Bronchus

181

13.5%

87

14.5%

94

12.8%

Trachea, Mediastinum and Other Respiratory Organs

1

0.1%

0

0.0%

1

0.1%

SKIN EXCLUDING BASAL & SQUAMOUS

45

3.3%

24

4.0%

21

2.8%

Melanoma - Skin

42

3.1%

22

3.7%

20

2.7%

Other Non=Epithelial Skin

3

0.2%

2

0.3%

1

0.1%

SOFT TISSUE (including heart)

1

0.1%

0

0.0%

1

0.1%

URINARY SYSTEM

95

7.1%

70

11.6%

25

3.4%

Kidney & Renal Pelvis

44

3.3%

29

4.8%

15

2.0%

Urinary Bladder

46

3.4%

38

6.3%

8

1.1%

Ureter

5

0.4%

3

0.5%

2

0.3%

MISCELLANEOUS

31

2.3%

14

2.3%

17

2.3%

1

0.1%

1

.2%

1

0.0%

Acute Myeloid Leukemia w/ Mutated RUNX1 Total

1,339

602

737